Laura T Pizzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5920895/publications.pdf

Version: 2024-02-01

		1163117	996975
23	246	8	15
papers	citations	h-index	g-index
23	23	23	386
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. Journal of Geriatric Oncology, 2018, 9, 526-533.	1.0	44
2	A community-integrated home based depression intervention for older African Americans: descripton of the Beat the Blues randomized trial and intervention costs. BMC Geriatrics, 2012, 12, 4.	2.7	35
3	Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer. Journal of Geriatric Oncology, 2017, 8, 296-302.	1.0	35
4	Embedding caregiver support in community-based services for older adults: A multi-site randomized trial to test the Adult Day Service Plus Program (ADS Plus). Contemporary Clinical Trials, 2019, 83, 97-108.	1.8	24
5	Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model. Applied Health Economics and Health Policy, 2018, 16, 889-899.	2.1	17
6	Costs of a community-based glaucoma detection programme: analysis of the Philadelphia Glaucoma Detection and Treatment Project. British Journal of Ophthalmology, 2018, 102, 225-232.	3.9	15
7	Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer. American Health and Drug Benefits, 2017, 10, 288-295.	0.5	13
8	Manhattan Vision Screening and Follow-up Study in Vulnerable Populations (NYC-SIGHT): Design and Methodology. Journal of Glaucoma, 2021, 30, 388-394.	1.6	11
9	Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2021, 37, 811-817.	1.9	7
10	Prevalence of depressive symptoms and associated factors in an urban, ophthalmic population. European Journal of Ophthalmology, 2021, 31, 740-747.	1.3	7
11	Competencies for Professionals in Health Economics and Outcomes Research: The ISPOR Health Economics and Outcomes Research Competencies Framework. Value in Health, 2020, 23, 1120-1127.	0.3	6
12	Cost–Benefit Analysis of the COPE Program for Persons Living With Dementia: Toward a Payment Model. Innovation in Aging, 2022, 6, igab042.	0.1	6
13	Assessing the impact of medically tailored meals and medical nutrition therapy on type 2 diabetes: Protocol for Project MiNT. Contemporary Clinical Trials, 2021, 108, 106511.	1.8	5
14	A randomized clinical trial of a collaborative home-based diabetes intervention to reduce emergency department visits and hospitalizations in black individuals with diabetes. Contemporary Clinical Trials, 2020, 95, 106069.	1.8	4
15	Exploring beliefs about pneumococcal vaccination in a predominantly older African American population: the Pharmacists' Pneumonia Prevention Program (PPPP). Ethnicity and Health, 2021, 26, 364-378.	2.5	4
16	Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results. Current Eye Research, 2021, 46, 1597-1604.	1.5	3
17	Cost of Purchased Versus Produced Plasma from Donor Recruitment Through Transfusion. Applied Health Economics and Health Policy, 2016, 14, 609-617.	2.1	2
18	Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review. Applied Health Economics and Health Policy, 2021, 19, 487-499.	2.1	2

#	Article	IF	CITATIONS
19	A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation in a Tertiary Eye Care Center. American Health and Drug Benefits, 2018, 11, 480-487.	0.5	2
20	Economic implications of FDA platelet bacterial guidance compliance options: Comparison of singleâ€step strategies. Transfusion, 2022, 62, 365-373.	1.6	2
21	Authors' Reply to Mintz: "Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model― Applied Health Economics and Health Policy, 2019, 17, 259-261.	2.1	1
22	Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports. American Health and Drug Benefits, 2020, 13, 136-142.	0.5	1
23	Costs of the Care for Older Persons with Dementia in their Environment (COPE) intervention when delivered through the Connecticut state Medicaid waiver program. Alzheimer's and Dementia, 2020, 16, e047584.	0.8	0